Latest Boehringer Ingelheim Stories
AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Ferring Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, Novartis, Novo Nordisk, Pearl Therapeutics, Pfizer, Sanofi, Chiltern
Third product from the BI-Lilly Diabetes alliance to be approved by FDA RIDGEFIELD, Conn., and INDIANAPOLIS, Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
DUBLIN, July 31, 2014 /PRNewswire/ -- Research and Markets has announced the addition
British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading
For U.S. Media Only RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S.
Dr. Erik R. Martinez appointed to lead LLOYD, Inc. Shenandoah, Iowa (PRWEB) July 15, 2014 LLOYD, Inc. has announced the appointment of Dr. Erik R.
WASHINGTON and RIDGEFIELD, Conn., July 15, 2014 /PRNewswire-USNewswire/ -- NCLR (National Council of La Raza) today released a report
- Findings from Phase II clinical study of investigational compound volasertib include response rate and new overall survival data. RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ --
RIDGEFIELD, Conn., July 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human
- Large; stout; burly.